Navigation Links
GlaxoSmithKline and the University of Edinburgh Agree to Collaborative Partnership for Drug Discovery

EDINBURGH, Scotland, Oct. 26, 2011 /PRNewswire/ -- GlaxoSmithKline (GSK) and the University of Edinburgh have agreed on a collaborative partnership to discover and develop medicines with the potential to treat severe acute pancreatitis.

The alliance will build on work by university researchers that recently uncovered a molecular mechanism believed to have a major role in triggering life-threatening multiple organ failure. The collaboration will integrate the deep biology and disease understanding of the academic group led by Damian Mole and Dr. Scott Webster of the University's College of Medicine and Veterinary Medicine with GSK's expertise in drug discovery and development.

"Despite treatment for severe acute pancreatitis, up to a quarter of people affected will die from an attack. By teaming up with GSK, we have the opportunity to turn our science into a medicine," said Mole. Webster added, "This is a great example of translating academic research. The alliance brings together our collective expertise in target biology and drug discovery to tackle an enormous unmet medical need."

Work on the project will be carried out both within GSK and at the College of Medicine and Veterinary Medicine located at the Edinburgh BioQuarter (, Scotland's flagship life sciences development.

Under the terms negotiated by the BioQuarter, the University will receive success-based financial support from GSK linked to reaching agreed milestones, as well as an undisclosed upfront payment and royalties on sales from any product that is successfully commercialized out of the collaboration.

This alliance comes through GSK's Discovery Partnerships with Academia (DPAc) team, a recently formed group designed to bring together the complementary skill sets of GSK and individual academic groups in the search for innovative medicines.

Dr. Diane Harbison, Head of Business Development at Edinburgh BioQuarter, said: "This collaborative partnership with a world-leader in drug discovery demonstrates the strength and depth of research being conducted here in Edinburgh. We are delighted to have been selected as one of just ten DPAc projects being awarded globally by GlaxoSmithKline."

About Edinburgh BioQuarter

At the heart of Scottish life sciences, Edinburgh BioQuarter is a joint venture between Alexandria Real Estate Equities, Inc, the NHS, the University of Edinburgh and Scottish Enterprise. Edinburgh BioQuarter commercializes world-leading medical research and brings investors, ideas and companies together at the BioQuarter campus on the outskirts of Edinburgh. For more information, visit

SOURCE Edinburgh BioQuarter
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. Ian Tomlinson Joins SBC Board as GlaxoSmithKline Representative Director
2. Regulus Therapeutics and GlaxoSmithKline Name a Third Alliance microRNA Target Triggering a Preclinical Milestone Payment
3. Isis Initiates Phase 1 Study of ISIS-TTRRx and Earns $5 Million Milestone Payment From GlaxoSmithKline
4. GlaxoSmithKline and Amplimmune Form Global Strategic Collaboration
5. FDA Advisory Committee Makes Favorable Recommendation for Cervarix, GlaxoSmithKlines Candidate Cervical Cancer Vaccine
6. Amgen to Collaborate With GlaxoSmithKline to Commercialize Denosumab in Europe for Postmenopausal Osteoporosis (PMO)
7. GlaxoSmithKline Completes Acquisition of Stiefel
8. GlaxoSmithKline and Stiefel to Create New World-Leading Specialist Dermatology Business
9. Shire and GlaxoSmithKline Enter Agreement to Co-promote VYVANSE(R) (lisdexamfetamine dimesylate) CII for the Treatment of Adults With ADHD
10. Human Genome Sciences to Receive $9 Million Milestone Payment Related to GlaxoSmithKline Initiation of Phase 3 Clinical Trial of Syncria(R) in Type 2 Diabetes
11. GlaxoSmithKline Reports Q4 and Year End Results 2008
Post Your Comments:
(Date:10/13/2015)... 13, 2015  According to Kalorama Information, the ... $102 billion by the end of 2015. Clinical ... industry, as it is estimated that approximately 80% ... tests. In addition to diagnosing patients, clinical lab ... progression, monitor drug treatment and conditions, and determine ...
(Date:10/13/2015)... ... October 13, 2015 , ... Exotic Automation & ... solutions and components, is opening its latest Parker Store retail location in Ann, ... Exotic’s second major expansion in Metropolitan Detroit in less than a year. The ...
(Date:10/13/2015)... ... October 13, 2015 , ... SonaCare Medical, LLC, ... that it received de novo clearance from the U.S. Food and Drug Administration ... of prostate tissue. Sonablate® is the first High Intensity Therapeutic Ultrasound (HITU) device ...
(Date:10/13/2015)... Jersey (PRWEB) , ... October 13, 2015 , ... ... enhance the educational opportunities for school age children in the areas of Science, ... for all sectors of the national economy, and the program aims to increase ...
Breaking Biology Technology:
(Date:10/1/2015)... , Oct. 1, 2015  Biometrics includes diverse ... human body characteristics, such as fingerprints, eye retinas, ... Adoption of biometrics technology has been constantly increasing ... last five years. In addition to the most ... fingerprint recognition, other means of biometric authentication are ...
(Date:9/30/2015)... global glucose monitoring device and diabetes management market is valued ... on the industry from Kalorama Information. Sales in the traditional glucose ... continuous glucose monitoring and sensor segment, according to the healthcare ... in its latest report, The Global Glucose Monitoring Market ... , ...
(Date:9/28/2015)... , Sept. 28, 2015 CLEAR, ... that its expedited traveler service is coming ... transforms travel, bringing a frictionless experience, serious ... "CLEAR offers our travelers an ... service," said Jim Smith , Executive ...
Breaking Biology News(10 mins):